Clinical Trial Update: A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD [Phase 1, Phase 2]

View source ↗

Summary

Pfizer conducted a Phase 1/2 study to evaluate the safety and efficacy of UK-369,003 in patients with chronic obstructive pulmonary disease. The trial has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• UK-369,003 (UK-369,003)

Snippet

Sponsor: Pfizer | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1, Phase 2 | Status: COMPLETED